🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT06649110
Recruiting Phase 1/2

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110 · tracked via the Priya Life Science UK tracker
Sponsor
Novartis Pharmaceuticals
Phase
Phase 1/2
Started
2024-10-24
Last updated
2026-07-21

Condition(s) studied

Healthy Volunteers, Pulmonary Arterial Hypertension

Investigational drug(s) / intervention(s)

LTPPlacebo

LTP: LTP001

Placebo: Placebo

Study summary

A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
Accepted
Part A Inclusion Criteria: * Healthy males and non-child-bearing potential females Part A Exclusion Criteria: * Clinically significant ECG or cardiac abnormalities, any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the participant in the study Other protocol-defined inclusion/exclusion criteria may apply. * For Japanese cohorts: participants per protocol should be first generation Japanese or up to third generation Japanese as defined in inclusion criteria 7 of the protocol. Part B Inclusion Criteria: -Confirmed diagnosis of PAH, pre-randomization PVR ≥400 dyn.sec.cm-5, treatment with stable doses of standard-of-care PAH therapies, 6-minute walk distance ≥ 150 m and ≤450 m. Part B Exclusion Criteria: Any surgical or medical condition which may place the participant at higher risk from his/her participation in the study Women of child-bearing potential unless they are using highly effective methods of contraception Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 24 hours after stopping study treatment. History of hypersensitivity to any of the study treatments or excipients Other protocol-defined inclusion / exclusion criteria may apply

Primary outcome measure(s)

Trial sites (87)

FacilityCityRegionStatus
Arizona Pulmonary Specialists Ltd Scottsdale Arizona Recruiting
UC Irvine Medical Center Orange California Recruiting
Stanford Medical Center Stanford California Recruiting
Univ Colorado Hospital Aurora Colorado Recruiting
Central Florida Pulmonary Group Orlando Florida Recruiting
University of South Florida Tampa Florida Recruiting
Emory University School of Medicine Atlanta Georgia Recruiting
U of Kansas Medical Center Kansas City Kansas Recruiting
Norton Infectious Diseases Specialists Louisville Kentucky Recruiting
Tufts Medical Center Boston Massachusetts Recruiting
Lahey Hospital and Medical Center Burlington Massachusetts Recruiting
Sky Integrative Medical Center SKYCRNG PPDS Ridgeland Mississippi Recruiting
Summit Health Eastside Clinic Bend Oregon Recruiting
Allegheny General Hospital Pittsburgh Pennsylvania Recruiting
Statcare Pulmonary Consultants Knoxville Tennessee Recruiting
PPD Development LP Austin Texas Recruiting
PPD Development LP Austin Texas Recruiting
UT Southwestern Medical Center Dallas Texas Recruiting
The University of Utah Salt Lake City Utah Recruiting
Pul Ass Richmond Inc P A R Richmond Virginia Recruiting
Novartis Investigative Site Buenos Aires Buenos Aires F.D. Recruiting
Novartis Investigative Site CABA Argentina Recruiting
Novartis Investigative Site Río Cuarto Argentina Recruiting
Novartis Investigative Site San Miguel de Tucumán Argentina Recruiting
Novartis Investigative Site Santa Fe Argentina Recruiting
Novartis Investigative Site Camperdown New South Wales Recruiting
Novartis Investigative Site Darlinghurst New South Wales Recruiting
Novartis Investigative Site New Lambton Heights New South Wales Recruiting
Novartis Investigative Site Adelaide South Australia Recruiting
Novartis Investigative Site Leuven Vlaams Brabant Recruiting
Novartis Investigative Site Porto Alegre Rio Grande do Sul Recruiting
Novartis Investigative Site Prague Czechia Recruiting
Novartis Investigative Site Prague Czechia Recruiting
Novartis Investigative Site Angers France Recruiting
Novartis Investigative Site Brest France Recruiting
Novartis Investigative Site Clamart France Recruiting
Novartis Investigative Site Grenoble France Recruiting
Novartis Investigative Site Montpellier France Recruiting
Novartis Investigative Site Nice France Recruiting
Novartis Investigative Site Pessac France Recruiting

+ 47 more sites — see the full list on the official registry below.

More Novartis Pharmaceuticals trials in the UK

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06649110 on ClinicalTrials.gov ↗ ← All trials in the UK